10
Administration of Pharmaceutical Molecules with the aim to
improve their pharmacological properties, PI Prof Th.
Mavromoustakos).
References
1. Carrier RL, Miller AL, Ahmed I (2007) The
utility of cyclodextrins for enhancing oral bioavailability. J Control Release 123:78–99
2. Kurkov S, Loftsson T (2013) Cyclodextrins.
Int J Pharm 453(1):167–180
3. Cal K, Centkowska K (2008) Use of cyclodextrins in topical formulations: practical aspects.
Eur J Pharm Biopharm 68(3):467–478
4. Del Valle EMM (2004) Cyclodextrins and their
uses: a review. Process Biochem 39:1033–1046
5. Loftsson T, Jarho P, Másson M, Järvinen T
(2005) Cyclodextrins in drug delivery. Expert
Opin Drug Deliv 2(2):335–351
6. Loftsson T, Hreinsdóttir D, Másson M (2005)
Evaluation of cyclodextrin solubilization of
drugs. Int J Pharm 302(1–2):18–28
7. Iványi R, Jicsinszky L, Juvancz Z, Roos N, Otta
K, Szejtli J (2004) Influence of (hydroxy)alkylamino substituents on enantioseparation ability of single-isomer amino-beta- cyclodextrin
derivatives in chiral capillary electrophoresis.
Electrophoresis 25(16):2675–2686
8. Loftsson
T,
Brewster
ME
(1996)
Pharmaceutical applications of cyclodextrins.
1. Drug solubilization and stabilization. J
Pharm Sci 85(10):1017–1025
9. Saenger W (1980) Cyclodextrin inclusion
compounds in research and industry. Angew
Chem Int Ed Engl 19:344–362
10. Hirayama F, Uekama K (1987) Methods of
investigating and preparing inclusion compounds. In: Duchene D (ed) Cyclodextrins
and their industrial uses. Les editions de Sante,
Paris, pp 131–172
11. Duchene D, Wouessidjewe D (1990)
Pharmaceutical uses of cyclodextrins and derivatives. Drug Dev Ind Pharm 16:2487–2499
12. Jacob S, Nair A (2018) Cyclodextrin complexes: perspective from drug delivery and formulation. Drug Dev Res 79:201–217
13. Figueiras A, Carvalho RA, Ribeiro L, TorresLabandeira JJ, Veiga FJ (2007) Solid-state
characterization and dissolution profiles of the
inclusion complexes of omeprazole with native
and chemically modified beta-cyclodextrin. Eur
J Pharm Biopharm 67:531–539
14. Irbesartan Monograph for Professionals.
Drugs.com. American Society of HealthSystem Pharmacists. Retrieved 3 March 2019
15. Losartan Potassium. The American Society
of Health-System Pharmacists. Retrieved 8
December 2017
16. Candesartan label (PDF). FDA. February 2016
17. Amidon GL, Lennernäs H, Shah VP, Crison
JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of
in vitro drug product dissolution and in vivo
bioavailability. Pharm Res 12(3):413–420
18. Waiver of In Vivo Bioavailability and
Bioequivalence Studies for ImmediateRelease Solid Oral Dosage Forms Based on
a Biopharmaceutics Classification System
Guidance for Industry, U.S. Department of
Health and Human Services Food and Drug
Administration Center for Drug Evaluation
and Research (CDER), December 2017
19. Olthof MR, Hollman PC, Katan MB (2001)
Chlorogenic acid and caffeic acid are absorbed
in humans. J Nutr 131(1):66–71
20. Hirose M, Takesada Y, Tanaka H, Tamano
S, Kato T, Shirai T (1998) Carcinogenicity
of antioxidants BHA, caffeic acid, sesamol,
4-methoxyphenol and catechol at low doses,
either alone or in combination, and modulation
of their effects in a rat medium-term multiorgan carcinogenesis model. Carcinogenesis
19(1):207–212
21. Basu Mallik S, Mudgal J, Nampoothiri
M, Hall S, Dukie SA, Grant G, Rao CM,
Arora D (2016) Caffeic acid attenuates
lipopolysaccharide- induced sickness behaviour
and neuroinflammation in mice. Neurosci Lett
632:218–223
22. Saller R, Brignoli R, Melzer J, Meier R (2008)
An updated systematic review with metaanalysis for the clinical evidence of silymarin.
Forsch Komplementmed 15(1):9–20
23. Hatcher H, Planalp R, Cho J, Torti FM, Tortic
SV (1631–1652) Curcumin: from ancient
medicine to current clinical trials. Cell Mol Life
Sci 65(11):2008
24. Flavonoids
(Review).
Micronutrient
Information Center, Linus Pauling Institute,
Oregon
State
University,
Corvallis,
OR. November 2015. Retrieved 1 April 2018
25. Leonis G, Ntountaniotis D, Christodoulou
E, Mavromoustakos T Effects of the complex
HP-β-CD with irbesartan on lipid bilayers containing cholesterol. Pharm J. https://www.
Eirini Christodoulou et al.
Administration of Pharmaceutical Molecules with the aim to
improve their pharmacological properties, PI Prof Th.
Mavromoustakos).
References
1. Carrier RL, Miller AL, Ahmed I (2007) The
utility of cyclodextrins for enhancing oral bioavailability. J Control Release 123:78–99
2. Kurkov S, Loftsson T (2013) Cyclodextrins.
Int J Pharm 453(1):167–180
3. Cal K, Centkowska K (2008) Use of cyclodextrins in topical formulations: practical aspects.
Eur J Pharm Biopharm 68(3):467–478
4. Del Valle EMM (2004) Cyclodextrins and their
uses: a review. Process Biochem 39:1033–1046
5. Loftsson T, Jarho P, Másson M, Järvinen T
(2005) Cyclodextrins in drug delivery. Expert
Opin Drug Deliv 2(2):335–351
6. Loftsson T, Hreinsdóttir D, Másson M (2005)
Evaluation of cyclodextrin solubilization of
drugs. Int J Pharm 302(1–2):18–28
7. Iványi R, Jicsinszky L, Juvancz Z, Roos N, Otta
K, Szejtli J (2004) Influence of (hydroxy)alkylamino substituents on enantioseparation ability of single-isomer amino-beta- cyclodextrin
derivatives in chiral capillary electrophoresis.
Electrophoresis 25(16):2675–2686
8. Loftsson
T,
Brewster
ME
(1996)
Pharmaceutical applications of cyclodextrins.
1. Drug solubilization and stabilization. J
Pharm Sci 85(10):1017–1025
9. Saenger W (1980) Cyclodextrin inclusion
compounds in research and industry. Angew
Chem Int Ed Engl 19:344–362
10. Hirayama F, Uekama K (1987) Methods of
investigating and preparing inclusion compounds. In: Duchene D (ed) Cyclodextrins
and their industrial uses. Les editions de Sante,
Paris, pp 131–172
11. Duchene D, Wouessidjewe D (1990)
Pharmaceutical uses of cyclodextrins and derivatives. Drug Dev Ind Pharm 16:2487–2499
12. Jacob S, Nair A (2018) Cyclodextrin complexes: perspective from drug delivery and formulation. Drug Dev Res 79:201–217
13. Figueiras A, Carvalho RA, Ribeiro L, TorresLabandeira JJ, Veiga FJ (2007) Solid-state
characterization and dissolution profiles of the
inclusion complexes of omeprazole with native
and chemically modified beta-cyclodextrin. Eur
J Pharm Biopharm 67:531–539
14. Irbesartan Monograph for Professionals.
Drugs.com. American Society of HealthSystem Pharmacists. Retrieved 3 March 2019
15. Losartan Potassium. The American Society
of Health-System Pharmacists. Retrieved 8
December 2017
16. Candesartan label (PDF). FDA. February 2016
17. Amidon GL, Lennernäs H, Shah VP, Crison
JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of
in vitro drug product dissolution and in vivo
bioavailability. Pharm Res 12(3):413–420
18. Waiver of In Vivo Bioavailability and
Bioequivalence Studies for ImmediateRelease Solid Oral Dosage Forms Based on
a Biopharmaceutics Classification System
Guidance for Industry, U.S. Department of
Health and Human Services Food and Drug
Administration Center for Drug Evaluation
and Research (CDER), December 2017
19. Olthof MR, Hollman PC, Katan MB (2001)
Chlorogenic acid and caffeic acid are absorbed
in humans. J Nutr 131(1):66–71
20. Hirose M, Takesada Y, Tanaka H, Tamano
S, Kato T, Shirai T (1998) Carcinogenicity
of antioxidants BHA, caffeic acid, sesamol,
4-methoxyphenol and catechol at low doses,
either alone or in combination, and modulation
of their effects in a rat medium-term multiorgan carcinogenesis model. Carcinogenesis
19(1):207–212
21. Basu Mallik S, Mudgal J, Nampoothiri
M, Hall S, Dukie SA, Grant G, Rao CM,
Arora D (2016) Caffeic acid attenuates
lipopolysaccharide- induced sickness behaviour
and neuroinflammation in mice. Neurosci Lett
632:218–223
22. Saller R, Brignoli R, Melzer J, Meier R (2008)
An updated systematic review with metaanalysis for the clinical evidence of silymarin.
Forsch Komplementmed 15(1):9–20
23. Hatcher H, Planalp R, Cho J, Torti FM, Tortic
SV (1631–1652) Curcumin: from ancient
medicine to current clinical trials. Cell Mol Life
Sci 65(11):2008
24. Flavonoids
(Review).
Micronutrient
Information Center, Linus Pauling Institute,
Oregon
State
University,
Corvallis,
OR. November 2015. Retrieved 1 April 2018
25. Leonis G, Ntountaniotis D, Christodoulou
E, Mavromoustakos T Effects of the complex
HP-β-CD with irbesartan on lipid bilayers containing cholesterol. Pharm J. https://www.
Eirini Christodoulou et al.